Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA)..

PLoS One. 2017 Mar 23;12(3):e0174656. doi: 10.1371/journal.pone.0174656. eCollection 2017. Erratum in: PLoS One. 2017 Apr 7;12 (4):e0175605.

2.

IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis.

Damen MS, Agca R, Holewijn S, de Graaf J, Dos Santos JC, van Riel PL, Fransen J, Coenen MJ, Nurmohamed MT, Netea MG, Dinarello CA, Joosten LA, Heinhuis B, Popa CD.

Sci Rep. 2017 Jan 30;7:41629. doi: 10.1038/srep41629.

3.

The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis.

Deodhar A, Bitman B, Yang Y, Collier DH.

Clin Rheumatol. 2016 Dec;35(12):3045-3052. Epub 2016 Oct 5.

4.

Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England.

Pujades-Rodriguez M, Duyx B, Thomas SL, Stogiannis D, Rahman A, Smeeth L, Hemingway H.

PLoS One. 2016 Mar 15;11(3):e0151245. doi: 10.1371/journal.pone.0151245. eCollection 2016.

5.

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients.

Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A.

J Am Heart Assoc. 2016 Jan 4;5(1). pii: e002867. doi: 10.1161/JAHA.115.002867.

6.
7.

Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature.

Ruscitti P, Cipriani P, Cantarini L, Liakouli V, Vitale A, Carubbi F, Berardicurti O, Galeazzi M, Valenti M, Giacomelli R.

J Med Case Rep. 2015 Jun 2;9:123. doi: 10.1186/s13256-015-0603-y. Review.

8.

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compán V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA.

Ann Rheum Dis. 2016 Jan;75(1):16-22. doi: 10.1136/annrheumdis-2015-207526. Epub 2015 May 19. Review. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.

9.

Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative.

Mackey RH, Kuller LH, Deane KD, Walitt BT, Chang YF, Holers VM, Robinson WH, Tracy RP, Hlatky MA, Eaton CB, Liu S, Freiberg MS, Talabi MB, Schelbert EB, Moreland LW.

Arthritis Rheumatol. 2015 Sep;67(9):2311-22. doi: 10.1002/art.39198.

10.
11.

Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study.

Corrales A, Dessein PH, Tsang L, Pina T, Blanco R, Gonzalez-Juanatey C, Llorca J, Gonzalez-Gay MA.

Arthritis Res Ther. 2015 Mar 11;17:55. doi: 10.1186/s13075-015-0576-7.

12.

Disease activity in rheumatoid arthritis and the risk of cardiovascular events.

Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, Hochberg MC, Tsao P, Greenberg JD.

Arthritis Rheumatol. 2015 Jun;67(6):1449-55. doi: 10.1002/art.39098.

13.

Utility of different cardiovascular disease prediction models in rheumatoid arthritis.

Purcarea A, Sovaila S, Udrea G, Rezus E, Gheorghe A, Tiu C, Stoica V.

J Med Life. 2014 Oct-Dec;7(4):588-94.

14.

Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis?

Purcarea A, Sovaila S, Gheorghe A, Udrea G, Stoica V.

J Med Life. 2014 Oct-Dec;7(4):461-7. Review.

15.

Angiotensin II in inflammation, immunity and rheumatoid arthritis.

Chang Y, Wei W.

Clin Exp Immunol. 2015 Feb;179(2):137-45. doi: 10.1111/cei.12467. Review.

16.

Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.

Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC.

Arthritis Care Res (Hoboken). 2015 Apr;67(4):457-66. doi: 10.1002/acr.22483.

17.

Cardiovascular disease risk amongst African black patients with rheumatoid arthritis: the need for population specific stratification.

Solomon A, Tsang L, Woodiwiss AJ, Millen AM, Norton GR, Dessein PH.

Biomed Res Int. 2014;2014:826095. doi: 10.1155/2014/826095. Epub 2014 Jul 23. Review.

18.

Adiponectin and atherosclerosis in rheumatoid arthritis.

Dessein PH, Tsang L, Solomon A, Woodiwiss AJ, Millen AM, Norton GR.

Mediators Inflamm. 2014;2014:358949. doi: 10.1155/2014/358949. Epub 2014 Jun 4.

19.

Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.

Mazilu D, Opriş D, Gainaru C, Iliuta M, Apetrei N, Luca G, Borangiu A, Gudu T, Peltea A, Groseanu L, Constantinescu C, Saulescu I, Bojinca V, Balanescu A, Predeteanu D, Ionescu R.

Biomed Res Int. 2014;2014:702701. doi: 10.1155/2014/702701. Epub 2014 May 20.

20.

Supplemental Content

Support Center